Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO
Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's ...
Bernstein Sticks to Their Buy Rating for Chugai Pharmaceutical Co (CHGCF)
Bernstein analyst Miki Sogi maintained a Buy rating on Chugai Pharmaceutical Co (CHGCF – Research Report) yesterday and set a price target of ...
Seeking Alpha7h
DSNKY Daiichi Sankyo Company, Limited
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...
BioPharma Dive1d
Enhertu, with new OK, set to supplant chemo in HER2-low breast cancer
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
As Trump and RFK Jr. move to upend drug making, Seattle biotech bets on science
Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...
ENDPOINTS NEWS2d
As­traZeneca and Dai­ichi Sanky­o's En­her­tu ap­proved in 'ul­tralow' HER2 pa­tients
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu is now approved to treat a new subset of breast cancer patients with very low levels of HER2 protein.
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients
FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant ...
FiercePharma3d
AZ, Daiichi's Enhertu nabs 7th FDA nod, including in 'HER2-ultralow' use, in breast cancer first
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
Explainer-Trump Tariffs on Chips and Drugs Would Hit U.S. Allies in Asia
Imposing tariffs on imported pharmaceuticals could weigh on Japan, home of major drugmakers such as Takeda, Astellas, Daiichi ...
PharmiWeb3d
Enhertu approved in the US as first HER2-directed…
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...